Dyadic International (NASDAQ:DYAI) Issues Quarterly Earnings Results

Dyadic International (NASDAQ:DYAI) posted its quarterly earnings data on Wednesday. The biotechnology company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02), FiscalAI reports. The company had revenue of $1.16 million for the quarter, compared to analyst estimates of $1.22 million. Dyadic International had a negative return on equity of 355.39% and a negative net margin of 134.84%.

Dyadic International Stock Performance

NASDAQ:DYAI opened at $0.94 on Thursday. The company has a quick ratio of 2.02, a current ratio of 2.02 and a debt-to-equity ratio of 5.40. Dyadic International has a fifty-two week low of $0.71 and a fifty-two week high of $2.20. The stock has a market cap of $34.07 million, a PE ratio of -4.95 and a beta of 1.00. The firm’s fifty day simple moving average is $1.07 and its 200-day simple moving average is $1.02.

Analyst Ratings Changes

DYAI has been the subject of several recent research reports. HC Wainwright assumed coverage on Dyadic International in a report on Thursday, October 23rd. They set a “buy” rating and a $3.00 price target for the company. Craig Hallum started coverage on shares of Dyadic International in a research note on Monday, September 8th. They issued a “buy” rating for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Dyadic International in a research note on Tuesday. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $3.00.

Institutional Trading of Dyadic International

An institutional investor recently raised its position in Dyadic International stock. Bank of America Corp DE boosted its stake in shares of Dyadic International Inc. (NASDAQ:DYAI) by 16,146.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 27,132 shares of the biotechnology company’s stock after buying an additional 26,965 shares during the quarter. Bank of America Corp DE owned 0.09% of Dyadic International worth $47,000 as of its most recent filing with the Securities and Exchange Commission. 27.95% of the stock is owned by institutional investors and hedge funds.

Dyadic International Company Profile

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.